Maia Biotechnology Inc at Precious Metals Summit Planet Microcap Showcase Transcript
Thank you all for coming. Now presenting Vlad Vitoc with MAIA Biotechnology, Inc.
Thank you all for coming. I'm the Founder and CEO of MAIA Biotechnology. It's a pleasure to be here today to represent the company. MAIA is an extraordinary company. We are the makers of the first telomere-targeting agent program.
THIO, our lead compound, is in the clinic. It's in a space to go to market, clinical trial. And the efficacy that we have seen with THIO in different models of cancer is absolutely outstanding. We have seen curative effect at doses 40 times under the maximum tolerated dose. Such a package of efficacy and safety is unprecedented.
The FDA has reviewed the data of THIO and granted THIO two Orphan Drug designations of the first two applications. Regeneron as well, via the clinical supply agreement, participated with their drug, Libtayo, an immune checkpoint inhibitor, into the Phase 2 THIO-101 trial in non-small cell lung cancer that is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
